Wikipedia
Debiopharm
Debiopharm Group (Debiopharm) is a family-owned biopharmaceutical group of companies headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay.
The group works through its subsidiaries:
- Debiopharm International SA, which in-licenses product candidates or technologies, develops them, and then licenses them to third parties for commercialization;
- Debiopharm Research and Manufacturing SA, which provides contract manufacturing and contract research services to Debiopharm;
- Debiopharm Investment SA, which manages the group's money and invests in real estate and in other companies; and
- Debiopharm Diagnostics SA, which invests in diagnostics companies.
As of 2010 two drugs had reached the market through its efforts: oxaliplatin for the treatment of cancer, and depot formulations of triptorelin, a gonadotropin-releasing hormone agonist that is used to treat prostate cancer and pedophilia in men, and in women, breast cancer, ovarian cancer, endometriosis, uterine fibromyomas, precocious puberty, and female infertility.